Pichia pastoris: A highly successful expression system for optimal synthesis of heterologous proteins

M Karbalaei, SA Rezaee… - Journal of cellular …, 2020 - Wiley Online Library
One of the most important branches of genetic engineering is the expression of recombinant
proteins using biological expression systems. Nowadays, different expression systems are …

[HTML][HTML] Chagas disease vaccine design: the search for an efficient Trypanosoma cruzi immune-mediated control

AE Bivona, AS Alberti, N Cerny, SN Trinitario… - … et Biophysica Acta (BBA …, 2020 - Elsevier
Chagas disease is currently endemic to 21 Latin-American countries and has also become a
global concern because of globalization and mass migration of chronically infected …

Harnessing RNA technology to advance therapeutic vaccine antigens against chagas disease

C Mancino, J Pollet, A Zinger, KM Jones… - … Applied Materials & …, 2024 - ACS Publications
Chagas disease (CD)(American trypanosomiasis caused by Trypanosoma cruzi) is a
parasitic disease endemic in 21 countries in South America, with increasing global spread …

Pichia pastoris (Komagataella phaffii) as a Cost-Effective Tool for Vaccine Production for Low- and Middle-Income Countries (LMICs)

S de Sá Magalhães, E Keshavarz-Moore - Bioengineering, 2021 - mdpi.com
Vaccination is of paramount importance to global health. With the advent of the more recent
pandemics, the urgency to expand the range has become even more evident. However, the …

The case for the development of a Chagas disease vaccine: why? How? When?

E Dumonteil, C Herrera - Tropical Medicine and Infectious Disease, 2021 - mdpi.com
Chagas disease is a major neglected tropical disease, transmitted predominantly by
triatomine insect vectors, but also through congenital and oral routes. While endemic in the …

Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection

A Sanchez Alberti, AE Bivona, N Cerny, K Schulze… - npj Vaccines, 2017 - nature.com
The parasite Trypanosoma cruzi is the causative agent of Chagas disease, a potentially life-
threatening infection that represents a major health problem in Latin America. Several …

Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+ Th1 specific immune responses and confers protection against …

MN Matos, SI Cazorla, K Schulze… - PLoS Neglected …, 2017 - journals.plos.org
The development of new adjuvants enables fine modulation of the elicited immune
responses. Ideally, the use of one or more adjuvants should result in the induction of a …

Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine

AE Bivona, A Sánchez Alberti, MN Matos… - PLoS Neglected …, 2018 - journals.plos.org
Background Chagas disease, also known as American Trypanosomiasis, is a chronic
parasitic disease caused by the flagellated protozoan Trypanosoma cruzi that affects about …

Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi

A Sanchez Alberti, AE Bivona, MN Matos… - Frontiers in …, 2020 - frontiersin.org
There are several unmet needs in modern immunology. Among them, vaccines against
parasitic diseases and chronic infections lead. Trypanosoma cruzi, the causative agent of …

Protective efficacy of the oral vaccine Tc24: Co1 produced in Schizochytrium sp. against Trypanosoma cruzi infection in a mouse model

A Ramos-Vega, VM Dzul-Huchim… - Microbial …, 2024 - Elsevier
Trypanosoma cruzi parasite–causal Chagas disease agent-affects about 7 million people;
no vaccine is available, and current medications have not been entirely effective …